inclusion criteria: 1. male and female between the ages of 18 and 45 years (inclusive). 2. body mass index in the range of 18.6-29.9 kg / m 2 inclusive; 3. verified diagnosis medically fit according to the data from standard clinical, laboratory and instrumental examination methods; 4. systolic blood pressure is not less than 100 mm hg and not higher than 130 mm hg ; diastolic blood pressure not less than 60 mm hg and not higher than 90 mm hg; pulse rate not less than 60 beats / min and not more than 90 beats / min, respiratory rate within 12-20 per minute; body temperature not less than 35.9 ° с and not more than 36.9 ° с. 5. the ability to understand and comprehend the explanation about the research; 6. willingness to comply with all procedures and restrictions associated with research; 7. the written informed consent of the volunteer to participate in the study in accordance with the current legislation, obtained before the start of any research procedures; 8. for women with preserved reproductive potential - a negative pregnancy test and consent to adhere to adequate contraceptive methods from the screening visit up to 180 days after the last intake of the study drug, inclusively, or lack of reproductive potential; 9. for men - consent to adhere to adequate contraceptive methods with partners with preserved reproductive potential from the first day of screening to 180 days after the last dose of the study drug, inclusive.

inclusion criteria: 1. male and female between the ages of 18 and 45 years (inclusive). 2. body mass index in the range of 18.6-29.9 kg / m 2 inclusive; 3. verified diagnosis medically fit according to the data from standard clinical, laboratory and instrumental examination methods; 4. systolic blood pressure is not less than 100 mm hg and not higher than 130 mm hg ; diastolic blood pressure not less than 60 mm hg and not higher than 90 mm hg; pulse rate not less than 60 beats / min and not more than 90 beats / min, respiratory rate within 12-20 per minute; body temperature not less than 35.9 ° с and not more than 36.9 ° с. 5. the ability to understand and comprehend the explanation about the research; 6. willingness to comply with all procedures and restrictions associated with research; 7. the written informed consent of the volunteer to participate in the study in accordance with the current legislation, obtained before the start of any research procedures; 8. for women with preserved reproductive potential - a negative pregnancy test and consent to adhere to adequate contraceptive methods from the screening visit up to 180 days after the last intake of the study drug, inclusively, or lack of reproductive potential; 9. for men - consent to adhere to adequate contraceptive methods with partners with preserved reproductive potential from the first day of screening to 180 days after the last dose of the study drug, inclusive.

inclusion criteria: male and female between the ages of 18 and 45 years (inclusive). body mass index in the range of 18.6-29.9 kg / m 2 inclusive; verified diagnosis medically fit according to the data from standard clinical, laboratory and instrumental examination methods; systolic blood pressure is not less than 100 mm hg and not higher than 130 mm hg ; diastolic blood pressure not less than 60 mm hg and not higher than 90 mm hg; pulse rate not less than 60 beats / min and not more than 90 beats / min, respiratory rate within 12-20 per minute; body temperature not less than 35.9 ° с and not more than 36.9 ° с. the ability to understand and comprehend the explanation about the research; willingness to comply with all procedures and restrictions associated with research; the written informed consent of the volunteer to participate in the study in accordance with the current legislation, obtained before the start of any research procedures; for women with preserved reproductive potential - a negative pregnancy test and consent to adhere to adequate contraceptive methods from the screening visit up to 180 days after the last intake of the study drug, inclusively, or lack of reproductive potential; for men - consent to adhere to adequate contraceptive methods with partners with preserved reproductive potential from the first day of screening to 180 days after the last dose of the study drug, inclusive.

inclusion criteria: male and female between the ages of 18 and 45 years (inclusive). body mass index in the range of 18.6-29.9 kg / m 2 inclusive; verified diagnosis medically fit according to the data from standard clinical, laboratory and instrumental examination methods; systolic blood pressure is not less than 100 mm hg and not higher than 130 mm hg ; diastolic blood pressure not less than 60 mm hg and not higher than 90 mm hg; pulse rate not less than 60 beats / min and not more than 90 beats / min, respiratory rate within 12-20 per minute; body temperature not less than 35.9 ° с and not more than 36.9 ° с. the ability to understand and comprehend the explanation about the research; willingness to comply with all procedures and restrictions associated with research; the written informed consent of the volunteer to participate in the study in accordance with the current legislation, obtained before the start of any research procedures; for women with preserved reproductive potential - a negative pregnancy test and consent to adhere to adequate contraceptive methods from the screening visit up to 180 days after the last intake of the study drug, inclusively, or lack of reproductive potential; for men - consent to adhere to adequate contraceptive methods with partners with preserved reproductive potential from the first day of screening to 180 days after the last dose of the study drug, inclusive.